Skip to content

Guidelines

TL;DR — The four major guideline families (EULAR 2017, Canadian 2012, German AWMF S3 2017, NICE NG193 2021) agree on the core: fibromyalgia is a positive clinical diagnosis managed primarily in primary care, starting with education and exercise, with drugs as second-line adjuncts at best (Macfarlane 2017, PMID 27377815; Fitzcharles 2013, PMID 23748251; Petzke 2017, PMID 28493229; Carville 2021, PMID 33883123). They diverge sharply on drugs: EULAR gives weak-for recommendations to duloxetine, pregabalin, and tramadol (Kia 2017, PMID 28536363); Germany restricts amitriptyline/duloxetine/pregabalin largely to comorbidity-defined subgroups; NICE says antiepileptics (including pregabalin), NSAIDs, benzodiazepines, and opioids "should not be offered" for chronic primary pain — directly contradicting the FDA fibromyalgia label for pregabalin, while NICE's antidepressant carve-out leaves room for duloxetine and milnacipran; the US-approved list has meanwhile grown to include sublingual cyclobenzaprine (2025) (Sommer 2017, PMID 28493231; Korwisi 2021, PMID 34712885; Sullivan 2026, PMID 41948806; Abd-Elsayed 2026, PMID 42479282). The divergence traces less to different data than to different methods: outcome weighting, inclusion criteria, and panel composition (Thieme 2017, PMID 28034828). Implementation everywhere lags: opioids — endorsed by no guideline beyond a Canadian tramadol carve-out — remain in common use.

The four major guidelines at a glance

Guideline Year Method / evidence grading Signature positions
EULAR revised recommendations (Macfarlane) 2017 (lit. to May 2015) Systematic reviews/meta-analyses only; GRADE; 107 reviews evaluated Only "strong for": exercise. All other recommended therapies — psychological therapies, pharmacotherapy, multimodal rehabilitation (the reviewed set spans CBT, mindfulness, acupuncture, hydrotherapy, amitriptyline, SNRIs, pregabalin) — graded "weak for". Graduated management: education + non-drug first; drugs targeted to severe pain/sleep disturbance (Macfarlane 2017, PMID 27377815)
Canadian Guidelines (Fitzcharles; CPS/CRA-endorsed) 2012 (pub. 2013) Oxford CEBM levels; needs-assessment driven; 2 summary papers FM is a positive clinical diagnosis, not exclusion, no specialist confirmation needed; care anchored in primary care; treatment symptom-based and patient-tailored; drugs give only "modest" benefit, doses often lower than trials; maintain workforce participation; discourage "culture of disablement" (Fitzcharles 2013, PMID 23748251; Fitzcharles 2013, PMID 23818709)
German AWMF S3 Leitlinie (145/004) 2017 update (1st ed. 2008) 13 societies + 2 patient organizations; 8 working groups (42 members) balanced for gender/expertise/COI; Oxford CEBM 2009; formal multi-step consensus (Häuser 2017, PMID 28493230) Strong: aerobic/strength exercise (Winkelmann 2017, PMID 28493223), meditative movement (Langhorst 2017, PMID 28493227), ≥24 h multimodal therapy for severe FM (Schiltenwolf 2017, PMID 28493228). Drugs: amitriptyline & duloxetine mainly with comorbid depression/anxiety; pregabalin with generalized anxiety; off-label use "can be considered" without comorbidity; strong opioids: not recommended (Sommer 2017, PMID 28493231). TMS, chiropractic, massage: not recommended (Winkelmann 2017, PMID 28493223)
NICE NG193, chronic primary pain (UK) 2021 NICE evidence review under ICD-11 chronic primary pain umbrella (FM subsumed, not FM-specific) Foremost non-drug care: physical activity/exercise, CBT-family therapy; a course of acupuncture and antidepressants may be offered; antiepileptics (incl. gabapentinoids), NSAIDs, benzodiazepines, opioids: do not offer for chronic primary pain; biofeedback, TENS, ultrasound not recommended (Carville 2021, PMID 33883123; Korwisi 2021, PMID 34712885; Kmietowicz 2021, PMID 33824137)

EULAR 2017 in detail

The revision replaced a 2008 expert-opinion document with one built exclusively on systematic reviews and meta-analyses (2,979 titles → 107 eligible reviews), graded with GRADE. Its structure is a graduated (stepped) approach with shared decision-making: (1) education and non-pharmacological therapy for all; (2) on non-response, therapy tailored to the clinical picture — psychological therapy for mood disorder/unhelpful coping, pharmacotherapy for severe pain or sleep disturbance, multimodal rehabilitation for severe disability. Exercise received the sole "strong for" recommendation; the authors are explicit that "the size of effect for most treatments is relatively modest" and set research priorities on predicting who benefits from which therapy (Macfarlane 2017, PMID 27377815). This makes EULAR 2017 the pivot document of the field: a rheumatology society formally demoting drugs below exercise — a reversal of its own 2008 emphasis on pharmacotherapy (noted in the guideline-comparison literature; Thieme 2017, PMID 28034828).

Canadian 2012 guidelines in detail

Framed around the pragmatics of care rather than modality rankings: FM presents as a spectrum of polysymptomatic distress with body pain as pivot; diagnosis is clinical, made in primary care without confirmatory tests or specialist sign-off; management combines non-pharmacologic and pharmacologic strategies with active patient participation and healthy lifestyle as the "cornerstone"; medications "afford only modest relief" and should be continually re-evaluated for risk–benefit; treatment goals are function and workforce retention, not symptom elimination (Fitzcharles 2013, PMID 23748251; Fitzcharles 2013, PMID 23818709). The Canadian document is unusual among guidelines for tolerating a weak-opioid (tramadol-first) trial — reserved for moderate–severe pain unresponsive to other treatment, with strong opioid use "discouraged" (full text, Recommendations 29–30; Fitzcharles 2013, PMID 23748251) — and for its explicit anti-disablement stance; it was also adopted for use in the United Kingdom (Thieme 2017, PMID 28034828).

German AWMF S3 guideline in detail

Methodologically the heaviest: 13 scientific societies plus two patient self-help organizations, coordinated by the German Pain Society, with working groups balanced for gender, discipline, hierarchy, and conflicts of interest; literature updated December 2010–May 2016; recommendations settled by formalized multi-step consensus; published in complete, short, clinical-practice, and patient versions (Häuser 2017, PMID 28493230). Distinctive positions:

  • Exercise: low-to-moderate intensity endurance and strength training strongly recommended (Winkelmann 2017, PMID 28493223).
  • Drug therapy is subgroup-gated: amitriptyline and duloxetine recommended in case of comorbid depression or generalized anxiety; pregabalin for generalized anxiety; duloxetine/pregabalin off-label use "can be considered" absent those comorbidities; strong opioids not recommended (Sommer 2017, PMID 28493231). Germany has no approved FM drug ("In Germany, no drug is specifically licensed for FMS"; Kia 2017, PMID 28536363; see the regulatory split in pharmacologic-therapy), so all use is off-label.
  • The accompanying editorial's title — "Twelve years of the S3 guideline Fibromyalgia Syndrome — a never-ending war?" — records how contested the guideline's terrain remains within German medicine (Häuser 2017, PMID 28493222; editorial without abstract, full text not retrieved) — context in history-and-nosology.
  • The update also carries etiology statements (biopsychosocial, no single causal factor) (Üçeyler 2017, PMID 28493226) and a pediatric part that reached no consensus on the label "juvenile fibromyalgia" while agreeing antidepressants/anticonvulsants should not be used for pain in children and adolescents (Draheim 2017, PMID 28493225).

NICE NG193 (2021) and the transatlantic contradiction

NG193 is not a fibromyalgia guideline: it covers assessment of all chronic pain and management of chronic primary pain (the ICD-11 umbrella that subsumes FM; see history-and-nosology). Its management core, as summarized in the published record: nonpharmacological interventions foremost (physical activity, CBT-family therapies); a course of acupuncture and antidepressants may be offered; benzodiazepines, antiepileptic drugs (the class containing pregabalin/gabapentin), NSAIDs, and opioids "should not be offered"; biofeedback, TENS, and therapeutic ultrasound not recommended (Carville 2021, PMID 33883123; Korwisi 2021, PMID 34712885; Kmietowicz 2021, PMID 33824137).

Consequences and controversy:

  • Transatlantic contradiction: a UK patient with FM should not be started on pregabalin per NICE, while the same drug carries an FDA fibromyalgia indication (since 2007), as do duloxetine, milnacipran, and now sublingual cyclobenzaprine/Tonmya (2025) (Briley 2010, PMID 20047155; Sullivan 2026, PMID 41948806). Notably, NICE's own evidence engine later produced the Cochrane NMA finding duloxetine the only antidepressant with moderate-certainty benefit — supporting NG193's antidepressant carve-out while underlining how thin the rest of the drug evidence is (Birkinshaw 2023, PMID 37160297).
  • The Pain Net critique (international researcher network): NICE wrongly treated absence of the new "CPP" label in older trials as absence of evidence; the one-size-fits-all CPP umbrella ignores syndrome-specific needs (its recommendations even contradict NICE's own migraine and IBS guidance); and NICE misclassified IBS as secondary pain, betraying conceptual confusion about the primary-pain construct (Korwisi 2021, PMID 34712885).
  • Reality check: in a ~1,000-person UK community survey mapped against NG193 as a baseline, 47% of chronic-pain respondents reported opioid use, and the authors predicted uptake of the de-prescribing recommendations would be slow (Zambelli 2022, PMID 36032346).

Where guidelines agree vs disagree

Agreement (effectively unanimous): - Exercise/physical activity is first-line and the strongest-evidence therapy (Macfarlane 2017, PMID 27377815; Winkelmann 2017, PMID 28493223; Carville 2021, PMID 33883123). - Education, explicit diagnosis communication, shared decision-making, and primary-care anchoring come first (Fitzcharles 2013, PMID 23748251; Petzke 2017, PMID 28493229). - Strong opioids should not be used (Sommer 2017, PMID 28493231; Korwisi 2021, PMID 34712885; Goldenberg 2016, PMID 26975749). - Drugs, where used at all, deliver modest average benefit and require ongoing risk–benefit review (Fitzcharles 2013, PMID 23818709; Macfarlane 2017, PMID 27377815).

Disagreement:

Issue EULAR 2017 Canadian 2012 German S3 2017 NICE NG193 2021
Pregabalin Weak-for (Kia 2017, PMID 28536363) Option (anticonvulsant class, modest benefit) Only with comorbid GAD; off-label "can be considered" Do not offer (antiepileptic class)
Duloxetine/SNRI Weak-for Option With comorbid depression/GAD Antidepressants may be offered
Amitriptyline Weak-for (low dose) Option (antidepressant class) With comorbid depression/GAD (antidepressant — may be offered)
Tramadol Weak-for Weak-opioid trial reserved for refractory moderate–severe pain (no position in retrieved summary; strong opioids not recommended) Do not offer (opioid class)
Acupuncture At best weak-for (not strong-for) — "Can be considered" Course may be offered (Kmietowicz 2021, PMID 33824137)
CBT ranking Weak for (targeted) Core option Strong within multimodal Foreground (CBT-family)
TMS — — Not recommended —

The systematic comparison of APS 2005, AWMF 2012, Canadian 2013, and EULAR 2016 guidelines found APS/CPS/AWMF gave their highest rankings to aerobic exercise, CBT, amitriptyline, and multicomponent therapy, while EULAR 2016 uniquely elevated exercise alone; the paper attributes inconsistencies to differing study-inclusion criteria, outcome measures, weighting systems, and panel composition (rheumatology- vs psychology- vs pain-society-led), and calls for a guideline consensus process (Thieme 2017, PMID 28034828). In other words: the same trial base, filtered through different methodological priors, yields different medicine.

Stepped care as the shared skeleton

All four documents converge on a severity-scaled algorithm even where drug lists differ: (1) confirmed positive diagnosis + education + lifestyle/exercise for everyone; (2) add targeted monotherapy (psychological or pharmacological, matched to dominant symptom/comorbidity) on non-response; (3) reserve intensive multicomponent/multimodal programs for severe presentations (Macfarlane 2017, PMID 27377815; Petzke 2017, PMID 28493229; Schiltenwolf 2017, PMID 28493228; Fitzcharles 2013, PMID 23818709). What no guideline yet specifies operationally: validated severity cut-points for stepping (the FIQ(R) bands proposed for trials — mild <39, moderate 39–<59, severe ≥59 — have not been adopted as care thresholds; Bennett 2009, PMID 19369473), or re-assessment intervals.

Implementation reality

  • Guideline-discordant prescribing persists at scale: opioid use in FM/chronic-pain populations remains common despite universal recommendations against (Goldenberg 2016, PMID 26975749; Zambelli 2022, PMID 36032346).
  • Patients rate rest, heat, and centrally acting drugs (including opioids and hypnotics) as most effective — a preference structure guidelines have not engaged with directly (Bennett 2007, PMID 17349056; patient-experience-and-advocacy).
  • The therapies all guidelines rank first (supervised exercise, CBT, multimodal programs) are the least available and reimbursed; digital delivery is the main scaling candidate (Gendreau 2024, PMID 38991582; non-pharmacologic-therapy).
  • A physiotherapy-journal appraisal critiqued EULAR 2017 from the implementation side (Arumugam 2019, PMID 30852147) — the "exercise" recommendation is strong, but programming specifics (type, dose, progression) are left to the implementer [appraisal detail: one-page item without abstract; full text not retrieved this session].

Open questions

  • Should FM guidelines exist at all, or should FM be governed by chronic-primary-pain umbrella guidance? NG193's one-size-fits-all approach was the first test and drew formal international objection (Korwisi 2021, PMID 34712885).
  • Can a formal consensus reconcile the drug-recommendation contradictions, as proposed by Thieme et al. (Thieme 2017, PMID 28034828)? None has occurred as of the 2017–2021 documents; whether the August 2025 Tonmya approval forces guideline updates is open (Sullivan 2026, PMID 41948806; Abd-Elsayed 2026, PMID 42479282).
  • What severity thresholds should trigger stepping-up, and do FIQ(R)-band-based steps improve outcomes vs clinician judgment (Bennett 2009, PMID 19369473)?
  • Does subgroup-gating drugs by psychiatric comorbidity (German model; Sommer 2017, PMID 28493231) outperform symptom-agnostic prescribing (FDA-label model)? No trial has compared the strategies.
  • EULAR's own research agenda — predicting which patient benefits from which modality (Macfarlane 2017, PMID 27377815) — remains unanswered a decade on; connects to biomarkers and omics-and-emerging-science.
  • AWMF S3 update status after 2017: a targeted PubMed search of Schmerz 2018–2026 (this session) found no post-2017 update of the FM guideline series — the 2017 papers (PMIDs 28493222–28493231) remain the latest PubMed-indexed version. When a revision appears, the subgroup-gated drug chapter is the section to re-check first.

References

  1. Macfarlane GJ, Kronisch C, Dean LE, et al. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2017;76:318-328. PMID 27377815
  2. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. 2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary. Pain Res Manag. 2013;18:119-26. PMID 23748251
  3. Fitzcharles MA, Ste-Marie PA, Goldenberg DL, et al. Canadian Pain Society and Canadian Rheumatology Association recommendations for rational care of persons with fibromyalgia: a summary report. J Rheumatol. 2013;40:1388-93. PMID 23818709
  4. Häuser W, Nothacker M. [Methodology report of the 2017 guidelines on fibromyalgia syndrome]. Schmerz. 2017;31:200-230. PMID 28493230
  5. Sommer C, Alten R, Bär KJ, et al. [Drug therapy of fibromyalgia syndrome: updated guidelines 2017 and overview of systematic review articles]. Schmerz. 2017;31:274-284. PMID 28493231
  6. Winkelmann A, Bork H, Brückle W, et al. [Physiotherapy, occupational therapy and physical therapy in fibromyalgia syndrome: updated guidelines 2017]. Schmerz. 2017;31:255-265. PMID 28493223
  7. Langhorst J, Heldmann P, Henningsen P, et al. [Complementary and alternative procedures for fibromyalgia syndrome: updated guidelines 2017]. Schmerz. 2017;31:289-295. PMID 28493227
  8. Schiltenwolf M, Eidmann U, Köllner V, et al. [Multimodal therapy of fibromyalgia syndrome: updated guidelines 2017]. Schmerz. 2017;31:285-288. PMID 28493228
  9. Petzke F, Brückle W, Eidmann U, et al. [General treatment principles, coordination of care and patient education in fibromyalgia syndrome: updated guidelines 2017]. Schmerz. 2017;31:246-254. PMID 28493229
  10. Häuser W, Kühn E, Wolf B, Nothacker M, Petzke F. [Twelve years of the S3 guideline Fibromyalgia Syndrome — a never-ending war?]. Schmerz. 2017;31:197-199. PMID 28493222
  11. Üçeyler N, Burgmer M, Friedel E, et al. [Etiology and pathophysiology of fibromyalgia syndrome: updated guidelines 2017]. Schmerz. 2017;31:239-245. PMID 28493226
  12. Draheim N, Ebinger F, Schnöbel-Müller E, Wolf B, Häuser W. [Definition, diagnostics and therapy of chronic widespread pain and the (so-called) fibromyalgia syndrome in children and adolescents: updated guidelines 2017]. Schmerz. 2017;31:296-307. PMID 28493225
  13. Carville S, Constanti M, Kosky N, Stannard C, Wilkinson C. Chronic pain (primary and secondary) in over 16s: summary of NICE guidance. BMJ. 2021;373:n895. PMID 33883123
  14. Korwisi B, Barke A, Kharko A, et al. Not really nice: a commentary on the recent version of NICE guidelines [NG193: chronic pain (primary and secondary) in over 16s] by the Pain Net. Pain Rep. 2021;6:e961. PMID 34712885
  15. Thieme K, Mathys M, Turk DC. Evidenced-based guidelines on the treatment of fibromyalgia patients: are they consistent and if not, why not? Have effective psychological treatments been overlooked? J Pain. 2017;18:747-756. PMID 28034828
  16. Zambelli Z, Halstead EJ, Iles R, Fidalgo AR, Dimitriou D. The 2021 NICE guidelines for assessment and management of chronic pain: a cross-sectional study mapping against a sample of 1,000 in the community. Br J Pain. 2022;16:439-449. PMID 36032346
  17. Birkinshaw H, Friedrich CM, Cole P, et al. Antidepressants for pain management in adults with chronic pain: a network meta-analysis. Cochrane Database Syst Rev. 2023;5:CD014682. PMID 37160297
  18. Briley M. Drugs to treat fibromyalgia - the transatlantic difference. Curr Opin Investig Drugs. 2010;11:16-8. PMID 20047155
  19. Sullivan GM, Meibohm B, Gould E, Daugherty BL, Lederman S. Steady-state pharmacokinetic properties of TNX-102 SL (approved as TONMYA) with daily dosing in healthy volunteers. Clin Pharmacol Drug Dev. 2026;15:e70060. PMID 41948806
  20. Goldenberg DL, Clauw DJ, Palmer RE, Clair AG. Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc. 2016;91:640-8. PMID 26975749
  21. Bennett RM, Jones J, Turk DC, Russell IJ, Matallana L. An internet survey of 2,596 people with fibromyalgia. BMC Musculoskelet Disord. 2007;8:27. PMID 17349056
  22. Bennett RM, Bushmakin AG, Cappelleri JC, Zlateva G, Sadosky AB. Minimal clinically important difference in the fibromyalgia impact questionnaire. J Rheumatol. 2009;36:1304-11. PMID 19369473
  23. Gendreau RM, McCracken LM, Williams DA, et al. Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial. Lancet. 2024;404:364-374. PMID 38991582
  24. Arumugam V, MacDermid JC. Appraisal of Clinical Practice Guideline: EULAR revised recommendations for the management of fibromyalgia. J Physiother. 2019;65:112. PMID 30852147
  25. Kia S, Choy E. Update on treatment guideline in fibromyalgia syndrome with focus on pharmacology. Biomedicines. 2017;5(2):20. PMID 28536363
  26. Kmietowicz Z. Offer exercise, therapy, acupuncture, or antidepressants for chronic primary pain, says NICE. BMJ. 2021;373:n907. PMID 33824137
  27. Abd-Elsayed A, Knezic A, Asfour J, Dewan P, Hasoon J, Reilly M. Sublingual cyclobenzaprine for fibromyalgia: pharmacokinetic rationale, clinical evidence, and place in therapy. Curr Pain Headache Rep. 2026;30(1). PMID 42479282